This description relates to methods and systems for combining medicine with an artificial sensory experience.
In one aspect, a method includes but is not limited to measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual and modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one or more various aspects, related systems include but are not limited to circuitry and/or programming for effecting the herein-referenced method aspects; the circuitry and/or programming can be virtually any combination of hardware, software, and/or firmware configured to effect the herein-referenced method aspects depending upon the design choices of the system designer.
In one aspect, a system includes but is not limited to means for measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual and means for modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one aspect, a system includes but is not limited to circuitry for measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual and circuitry for modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one aspect, a computer program product includes but is not limited to a signal-bearing medium bearing one or more instructions for measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual and one or more instructions for modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
In one aspect, a system includes but is not limited to a computing device and instructions that when executed on the computing device cause the computing device to measure at least one effect of a combined bioactive agent and artificial sensory experience on an individual and modify at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect. In addition to the foregoing, other method aspects are described in the claims, drawings, and text forming a part of the present disclosure.
The foregoing is a summary and thus may contain simplifications, generalizations, inclusions, and/or omissions of detail; consequently, those skilled in the art will appreciate that the summary is illustrative only and is NOT intended to be in any way limiting. Other aspects, features, and advantages of the devices and/or processes and/or other subject matter described herein will become apparent in the teachings set forth herein.
In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented here.
After a start operation, the operational flow 200 moves to an operation 210. Operation 210 depicts accepting at least one attribute of at least one individual. For example, as shown in
Then, operation 220 depicts querying at least one database at least partly based on the at least one attribute. For example, as shown in
Then, operation 230 depicts selecting from the at least one database at least one prescription medication and at least one artificial sensory experience to address the at least one attribute of at least one individual. For example, as shown in
Then, operation 240 depicts presenting an indication of the at least one prescription medication and the at least one artificial sensory experience at least partly based on the selecting from the at least one database at least one prescription medication and at least one artificial sensory experience to address the at least one attribute of at least one individual. For example, as shown in
Operation 302 illustrates accepting at least one physical enhancement goal associated with the at least one individual. For example, as shown in
Operation 402 illustrates accepting at least one physical attribute associated with the at least one individual. For example, as shown in
Operation 404 illustrates accepting at least one physical symptom associated with the at least one individual. For example, as shown in
Operation 406 illustrates accepting at least one of an indication or a measurement of at least one of pain, hypertension, sweating, dizziness, lightheadedness, abnormal respiration, headache, fatigue, nausea, fever, abnormal heart rhythm, motor weakness, or abnormal heart rate. For example, as shown in
Operation 504 illustrates accepting at least one of a disease, an illness, or a bodily impairment. For example, as shown in
Operation 704 illustrates accepting at least one diagnosis of at least one of a cardiovascular disorder, a digestive disorder, an endocrine disorder, a hearing disorder, an immune disorder, an inner ear disorder, an integumentary disorder, a lymphatic disorder, a muscular disorder, a nervous system disorder, a reproductive disorder, a respiratory disorder, a skeletal disorder, a visual disorder, or an urinary disorder. For example, as shown in
Operation 802 illustrates accepting at least one of a current treatment or a proposed treatment associated with the at least one individual. For example, as shown in
Operation 804 illustrates accepting the at least one attribute from a medical history associated with the at least one individual. For example, as shown in
Operation 806 illustrates accepting the at least one attribute from a personal medical history associated with at least one individual. For example, as shown in
Operation 808 illustrates accepting the at least one attribute from a family medical history associated with the at least one individual. For example, as shown in
Operation 902 illustrates accepting at least one mental enhancement goal associated with the at least one individual. For example, as shown in
Operation 1002 illustrates accepting at least one mental attribute associated with the at least one individual. For example, as shown in
Operation 1004 illustrates accepting at least one mental symptom associated with the at least one individual. For example, as shown in
Operation 1006 illustrates accepting at least one indication of anxiety, an appearance, a behavior, depression, fear, inattention, a mood disturbance, a phobia, or a psychological test result. For example, as shown in
Operation 1102 illustrates accepting at least one measurement associated with at least one of brain activity, cardiac activity, vascular activity, peripheral neural signals, hemodynamic activity, or metabolic activity. For example, as shown in
Operation 1202 illustrates accepting at least one mental impairment associated with at least one individual. For example, as shown in
Operation 1204 illustrates accepting at least one indication of at least one of a mood disorder, an anxiety disorder, a psychotic disorder, an eating disorder, a developmental disorder, a phobia, a communication disorder, a social disorder, or a personality disorder. For example, as shown in
Operation 1304 illustrates accepting at least one of a depression, a phobia, an anxiety disorder, a personality disorder, a psychotic disorder, a developmental disorder, a panic disorder, a bipolar disorder, schizophrenia, an eating disorder, obsessive compulsive disorder, post traumatic stress disorder, an attentional disorder, a communication disorder, a social disorder, or a mood disorder. For example, as shown in
Operation 1502 illustrates accepting the at least one attribute associated with the at least one individual from a health care provider. For example, as shown in
Operation 1504 illustrates accepting the at least one attribute associated with the at least one individual from a licensed health care provider. For example, as shown in
Operation 1506 illustrates accepting the at least one attribute associated with the at least one individual from an alternative medicine provider. For example, as shown in
Operation 1602 illustrates searching at least one prescription medication database and at least one artificial sensory experience database. For example, as shown in
Operation 1702 illustrates selecting the at least one prescription medication from a physician's desk reference database. For example, as shown in
Operation 1704 illustrates selecting at least one of an analgesic, an antacid, an antiarrhythmic, an antibacterial, an antibiotic, an anticoagulant, a thrombolytic, an anticonvulsant, an antidiarrheal, an antiemetic, an antifungal, an anti-allergic agent, an antihistamine, an antihypertensive, an anti-anginal, an anti-asthmatic, an anti-inflammatory, an antineoplastic, an antipyretic, an antiviral, an anti-ulcer agent, an antidyspeptic, an antacid, a beta-blocker, a bronchodilator, a cold treatment, a corticosteroid, an antitussive, a cytotoxic agent, a decongestant, a diuretic, an expectorant, a hormone, a hypoglycemic, an immunosuppressive, a laxative, a muscle relaxant, a sedative, a female sex hormone, a male sex hormone, a tranquilizer, an appetite modulator, or a vitamin. For example, as shown in
An antiarrhythmic may include a drug for controlling a heartbeat irregularity. Some examples of an antiarrhythmic may include a beta blocker such as propanolol, and/or lidocaine, verapamil, and/or quinidine. An antibacterial may include a drug used to treat an infection. Some examples of an antibacterial may include amoxicillin and/or ciprofloxacin. An antibiotic may include a drug made from naturally occurring and/or synthetic substances for combating a bacterial infection. Some examples of an antibiotic may include penicillin, streptomycin, and/or sulfonamide-based drugs. An anticoagulant may include an agent for preventing blood clots. An example of an anticoagulant may include a vitamin K antagonist, such as warfarin, and/or aspirin. A thrombolytic may help dissolve and disperse a blood clot and may be prescribed for patients with recent arterial or venous thrombosis. A thrombolytic may be derived from Streptomyces spp. and/or recombinant DNA technology and may include streptokinase, urokinase, and/or a tissue plasminogen activator (TPA) such as alteplase.
An anticonvulsant may include a pharmaceutical administered for the prevention of seizures. Some examples of an anticonvulsant may include a barbiturate, a carbamate, a fatty acid derivative, and/or a sulfonamide. An antidiarrheal may include a drug utilized for the relief of diarrhea. Some examples of an antidiarrheal may include an antispasmodic such as diphenoxylate and loperamide, a bismuth compound, a bulking agent, and/or an absorbent. An antiemetic may include a drug used to treat nausea and vomiting. Some examples of an antiemetic may include a 5-HT3 receptor antagonist, a dopamine antagonist, and/or a histamine. An antifungal may include a drug used to treat fungal infections, the most common of which affect the hair, skin, nails, and/or mucous membranes. Some examples of antifungals may include polyene antifungals, imidazole and triazole antifungals, and/or allylamines. An anti-allergenic agent may include an agent characterized by preventing and/or reducing the effect of an allergen. Some examples of an anti-allergenic may include an antihistamine, cortisone, hydrocortisone, and/or epinephrine. An antihistamine may include an agent used for counteracting the effects of histamine. Some examples of an antihistamine may include a H1-receptor antagonist and/or a H2-receptor antagonist. An antihypertensive may include drugs utilized for towering blood pressure. Some examples of an antihypertensive may include a diuretic, an adrenergic receptor antagonist, and/or an ACE inhibitor. An anti-anginal may include an agent used for preventing and/or reducing angina and/or chest pain. Some examples of an anti-anginal may include aspirin, ranolazine, and/or ivabradine. An anti-asthmatic may include an agent for preventing and/or reducing asthma and/or its effects. Some examples of an anti-asthmatic may include albuterol, an inhaled steroid, for example budesonide or fluticasone, and/or ipratropium bromide.
An anti-inflammatory may include an agent utilized to reduce inflammation and/or to treat redness, heat, swelling, and/or increased blood flow associated for example, that seen with an infection or injury, or in many chronic diseases such as rheumatoid arthritis and gout. Some anti-inflammatories may include steroids, and/or NSAIDs such as naproxen, ibuprofen, and/or aspirin. An antineoplastic may include drugs used to treat cancer and to inhibit and/or prevent the development of tumors. Some antineoplastics may include alkylating agents, antimetabolites, enzymes, enzyme inhibitors, immune modulators, and taxoids. An antipyretic may include a drug used to reduce a fever. Some examples of an antipyretic may include aspirin and/or acetaminophen. An antiviral may include a drug used to treat viral infections and/or to provide temporary protection against viral infections such as influenza. Some examples of an antiviral may include an interferon, acyclovir, ribavirin, and/or oseltamivir. An anti-ulcer agent may include an agent used for preventing and/or lessening the effect of an ulcer, including stomach ulcers, mouth ulcers, or other types of ulcers. Some examples of an anti-ulcer agent may include a bismuth compound, a prostaglandin analogue, and/or cimetidine. An antidyspeptic may include an agent used for treating and/or preventing dyspepsia. Some examples of an antidyspeptic may include simethicone and/or a proton pump inhibitor, such as esomeprazole. An antacid may include a substance, often a base, which may counteract stomach acidity. Some examples of an antacid may include magnesium hydroxide, aluminum hydroxide, calcium carbonate, and/or bismuth subsalicylate. A beta-blocker may include a beta-adrenergic blocking agent utilized for reducing the oxygen needs of the heart by reducing the heartbeat rate. Some examples of a beta-blocker may include propranolol, esmolol, bisoprolol, and/or timolol. A bronchodilator may include an agent utilized for opening the bronchial tubes within the lungs when the tubes have become narrowed, for example, by muscle spasm and may be used for treating asthma. Some examples of a bronchodilator may include albuterol and/or ipratropium bromide. A cold treatment may include an agent utilized for treating aches, pains, and/or fever accompanying a cold. Some cold treatments may include aspirin, acetaminophen, a decongestant, an antihistamine, and/or caffeine.
A corticosteroid may include a hormonal preparation used as an anti-inflammatory for arthritis or asthma and/or treating some malignancies or compensating for a deficiency of natural hormones. Some examples of a corticosteroid may include cortisol and/or aldosterone. A cough suppressant may include an agent used to soothe irritation caused by coughing and/or to prevent coughing. Some examples of a cough suppressant may include codeine, an antihistamine, and/or dextromethorphan. An antitussive may include a cough suppressant. A cytotoxic agent may include a drug used for killing and/or damaging cells. Some examples of a cytotoxic agent may include actinomycin-D, azathioprine, bleomycin, melphalan, busulphan, doxorubicin, etoposide, an antineoplastic agent, and/or an apoptotic agent. A decongestant may include an agent for reducing the swelling of the mucous membranes lining the nose and/or throat. Some examples of a decongestant may include pseudoephedrine and phenylephrine. A diuretic may include an agent for increasing the quantity of urine produced by the kidneys and passed out of the body. Some examples of a diuretic may include hydrochlorothiazide, spironolactone, mannitol, and/or glucose. An expectorant may include an agent for stimulating the flow of saliva, loosening and thinning mucus in airways, and/or promoting a more productive cough as to eliminate phlegm from the respiratory tract. An example of an expectorant may include guaifenesin. A hormone may include molecules produced naturally by the endocrine glands. Some examples of a hormone may include steroid hormones, amine-derived hormones, peptide hormones, and/or lipid and phospholipid-derived hormones. A hypoglycemic may include an agent for lowering the level of glucose in the blood. Some examples of a hypoglycemic may include a sulfonylurea, a meglitinide, a biguanide, a thiazolidinedione, and/or a alpha-glucosidase inhibitor. An immunosuppressive may include an agent for preventing or reducing the body's normal reaction to invasion by disease and/or foreign tissues. Some examples of an immunosuppressive may include a drug such as a corticosteroid, cyclosporine, rapamycin, which acts on immunophilins, and/or an antibody.
A laxative may include an agent for increasing the frequency and ease of bowel movements. Some examples of a laxative may include methylcellulose, docusate, mineral oil, and/or magnesium hydroxide. A muscle relaxant may include an agent utilized for relieving muscle spasms. Some examples of a muscle relaxant may include neuromuscular blocking drugs, carisoprodol, cyclobenzaprine, metaxalone, a benzodiazepine and/or a tranquilizer. A sedative may include a substance which depresses the central nervous system and may result in calmness, relaxation, reduction of anxiety, sleepiness, and/or slowed breathing. Some examples of a sedative may include zolpidem, and/or eszopiclone. A female sex hormone may include a hormone responsible for the development of female secondary sexual characteristics. Some examples of a female sex hormone may include estrogen and progesterone. A mate sex hormone may include a hormone responsible for the development of secondary male sexual characteristics. One example of a mate sex hormone may include testosterone. Sex hormone-related agents may include agents metabolically related to sex hormones. Examples of sex hormone-related agents may include sterols, androgens (testosterone), progestogens estrogens (estradiols, estrone), follicle-stimulating hormone, luteinizing hormone, inhibin B, anti-Mullerian hormone thyroid-related hormones. A tranquilizer may include any drug having a calming and/or sedative effect. Some examples of a tranquilizer may include an antidepressant, a barbiturate, and/or a benzodiazepine. An appetite modulator may include an agent used for regulating and/or adjusting appetite. Some examples of an appetite modulator may include recombinant PYY 3-36 and/or sibutramine. A vitamin may include chemicals essential in relatively small quantities for good health. Some examples of a vitamin may include Vitamin A, Vitamin C, Vitamin D, and/or Vitamin K.
In one instance, selector module 106 can select an analgesic and an antipsychotic for subsequent presentation, perhaps in response to accepting a pain symptom and a hallucination symptom as the at least one attribute. In some instances, selector module 106 may include a computer processor.
Operation 1902 illustrates selecting the at least one prescription medication at least partially based on at least one of a behavior, a symptom, or a diagnosis. For example, as shown in
Operation 1904 illustrates selecting the at least one prescription medication at least partially based on at least one of a susceptibility to a drug side effect or a drug interaction. For example, as shown in
Operation 1906 illustrates selecting a prescription medication and at least one alternative medicine treatment as the at least one prescription medication. For example, as shown in
Operation 2002 illustrates selecting the at least one prescription medication at least partially based on at least one of a medication history of the at least one individual or an artificial sensory experience history of the at least one individual. For example, as shown in
Operation 2004 illustrates selecting the at least one prescription medication at least partially based on at least one of a genetic or an epigenetic profile. For example, as shown in
Operation 2102 illustrates selecting at least one virtual experience as the at least one artificial sensory experience. For example, as shown in
Operation 2104 illustrates selecting at least one of a virtual world, a social networking website, an online game, an online educational experience, a networked game, or a single-player game. For example, as shown in
Operation 2202 illustrates selecting at least one real-world sensory stimulus as the at least one artificial sensory experience. For example, as shown in
Operation 2302 illustrates selecting the at least one artificial sensory experience at least partially based on at least one of a behavior, a symptom, or a diagnosis. For example, as shown in
Operation 2304 illustrates selecting the at least one artificial sensory experience at least partially based on at least one demographic characteristic of the at least one individual. For example, as shown in
Further, operation 2306 illustrates selecting the at least one artificial sensory experience at least partially based on at least one of geographic location, family status, age, gender, weight, ethnicity, body mass index, household size, or income of the at least one individual. For example, as shown in
Operation 2402 illustrates selecting the at least one artificial sensory experience at least partially based on at least one of a medication history or an artificial sensory experience history of the at least one individual. For example, as shown in
Operation 2404 illustrates selecting a preferred artificial sensory experience and at least one alternative artificial sensory experience. For example, as shown in
Operation 2502 illustrates selecting at least one artificial sensory experience and at least one prescription medication at least partially based on a treatment algorithm. For example, as shown in
Further, operation 2504 illustrates selecting at least one prescription medication at least partially based on at least one of a drug allergy associated with the at least one individual or a drug interaction associated with the at least one prescription medication. For example, as shown in
Operation 2506 illustrates selecting at least one opioid analgesic and at least one virtual world experience to address at least one pain attribute of at least one individual. For example, as shown in
Operation 2602 illustrates presenting an indication of a preferred combination including at least one prescription medication and at least one artificial sensory experience and at least one alternative combination including at least one alternative prescription medication and at least one alternative artificial sensory experience. For example, as shown in
Operation 2604 illustrates presenting an indication of the at least one prescription medication and the at least one artificial sensory experience to at least one output device. For example, as shown in
Further, operation 2606 illustrates presenting an indication of at least one of the at least one prescription medication or the at least one artificial sensory experience to at least one user interface. For example, as shown in
Operation 2802 illustrates presenting to a health care provider an indication of at least one of the at least one prescription medication or the at least one artificial sensory experience at least partly based on the selecting at least one prescription medication and at least one artificial sensory experience to address the at least one attribute of at least one individual. For example, as shown in
Operation 2804 illustrates presenting an indication of the at least one prescription medication or the at least one artificial sensory experience at a staggered time. For example, as shown in
After a start operation, the operational flow 2900 moves to an operation 2910. Operation 2910 depicts querying at least one database at least partly based on at least one attribute of an individual. For example, as shown in
Then, operation 2920 depicts selecting from the at least one database at least one prescription medication to address the at least one attribute of at least one individual. For example, as shown in
Then, operation 2930 depicts implementing at least one artificial sensory experience to address the at least one attribute of at least one individual in response to a selected at least one prescription medication. For example, as shown in
The computing device 3102 includes computer-executable instructions 3110 that when executed on the computing device 3102 cause the computing device 3102 to accept at least one attribute of at least one individual; query at least one database at least partly based on the at least one attribute; select from the at least one database at least one prescription medication and at least one artificial sensory experience to address the at least one attribute of at least one individual; and present an indication of the at least one prescription medication and the at least one artificial sensory experience at least partly based on the selecting from the at least one database at least one prescription medication and at least one artificial sensory experience to address the at least one attribute of at least one individual. As referenced above and as shown in
In
The device 3104 may include, for example, a portable computing device, workstation, or desktop computing device. In another example embodiment, the computing device 3102 is operable to communicate with the device 3104 associated with the user 118 to receive information about the input from the user 118 for performing data access and data processing and presenting an output of the user-health test function at least partly based on the user data.
Although a user 118 is shown/described herein as a single illustrated figure, those skilled in the art will appreciate that a user 118 may be representative of a human user, a robotic user (e.g., computational entity), and/or substantially any combination thereof (e.g., a user may be assisted by one or more robotic agents). In addition, a user 118, as set forth herein, although shown as a single entity may in fact be composed of two or more entities. Those skilled in the art will appreciate that, in general, the same may be said of “sender” and/or other entity-oriented terms as such terms are used herein.
As further illustrated in
System 3200 generally represents instrumentality for measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual, modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect, modifying an artificial sensory experience to enhance the efficacy of the bioactive agent, and/or presenting an indication of a modified combined bioactive agent and artificial sensory experience at least partially based on a modified at least one bioactive agent or artificial sensory experience. The operations of measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual, modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect, modifying an artificial sensory experience to enhance the efficacy of the bioactive agent, and/or presenting an indication of a modified combined bioactive agent and artificial sensory experience at least partially based on a modified at least one bioactive agent or artificial sensory experience may be accomplished electronically, such as with a set of interconnected electrical components, an integrated circuit, and/or a computer processor.
After a start operation, the operational flow 3600 moves to operation 3610. Operation 3610 depicts measuring at least one effect of a combined bioactive agent and artificial sensory experience on an individual. For example, as shown in
Then, operation 3620 depicts modifying at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect. For example, as shown in
Operation 3702 illustrates comparing empirical data with a current effect measurement. For example, as shown in
Operation 3704 illustrates measuring the at least one effect at least one of during or after the individual experiences the combined bioactive agent and artificial sensory experience. For example, as shown in
Further, operation 3706 illustrates utilizing at least one laboratory test to measure the at least one effect. For example, as shown in
Operation 3802 illustrates measuring the at least one effect with a self assessment. For example, as shown in
Operation 3804 illustrates measuring the at least one effect with a computerized assessment. For example, as shown in
Operation 3902 illustrates measuring an expected behavior. For example, as shown in
Further, operation 3904 illustrates comparing current measured behavior data with expected behavior data. For example, as shown in
Operation 4002 illustrates modifying access to at least a portion of the artificial sensory experience to alter at least one effect of the bioactive agent. For example, as shown in
Further, operation 4004 illustrates restricting access to at least a portion of the artificial sensory experience. For example, as shown in
Operation 4102 illustrates modifying a visual object in an artificial sensory experience to alter at least one effect of the bioactive agent. For example, as shown in
Further, operation 4104 illustrates modifying a color scheme of an artificial sensory experience to alter at least one effect of the bioactive agent. For example, as shown in
Operation 4202 illustrates altering a sound in an artificial sensory experience. For example, as shown in
Operation 4302 illustrates modifying a bioactive agent dosage. For example, as shown in
Operation 4304 illustrates modifying at least one bioactive agent in a bioactive agent combination. For example, as shown in
Operation 4306 illustrates modifying a bioactive agent delivery method. For example, as shown in
Operation 4308 illustrates modifying an artificial sensory experience to enhance the efficacy of the bioactive agent. For example, as shown in
Operation 4402 illustrates modifying an artificial sensory experience to reduce a side effect of the bioactive agent. For example, as shown in
Operation 4404 illustrates adding at least one of visual or audio content to the artificial sensory experience. For example, as shown in
Operation 4406 illustrates deleting at least one of visual or audio content of the artificial sensory experience. For example, as shown in
Operation 4408 illustrates adding content to the artificial sensory experience and deleting different content of the artificial sensory experience. For example, as shown in
Operation 4502 illustrates modifying a sensate experience to alter the at least one effect of the bioactive agent. For example, as shown in
Operation 4602 illustrates modifying an artificial sensory experience implemented on a mobile device. For example, as shown in
Operation 4604 illustrates measuring at least one effect of a pain medication and modifying a virtual world experience to alter at least one effect of the pain medication. For example, as shown in
Operation 4606 illustrates measuring at least one effect of an anti-depressant medication prescribed for the individual and modifying at least one cheerful attribute in a virtual world experience. For example, as shown in
After a start operation, operation 3610, and operation 3620, the operational flow 4700 moves to operation 4710. Operation 4710 illustrates presenting an indication of a modified combined bioactive agent and artificial sensory experience at least partially based on a modified at least one bioactive agent or artificial sensory experience. For example, as shown in
Operation 4712 illustrates presenting to at least one output device. For example, as shown in
Operation 4802 illustrates presenting to a third party. For example, as shown in
The computing device 5002 includes computer-executable instructions 5010 that when executed on the computing device 5002 cause the computing device 5002 to measure at least one effect of a combined bioactive agent and artificial sensory experience on an individual and modify at least one of the bioactive agent or the artificial sensory experience at least partially based on the at least one effect. As referenced above and as shown in
In
The device 5004 may include, for example, a portable computing device, workstation, or desktop computing device. In another example embodiment, the computing device 5002 is operable to communicate with the device 5004 associated with the user 118 to receive information about the input from the user 118 for performing data access and data processing and presenting an output of the user-health test function at least partly based on the user data.
Although a user 118 is shown/described herein as a single illustrated figure, those skilled in the art will appreciate that a user 118 may be representative of a human user, a robotic user (e.g., computational entity), and/or substantially any combination thereof (e.g., a user may be assisted by one or more robotic agents). In addition, a user 118, as set forth herein, although shown as a single entity may in fact be composed of two or more entities. Those skilled in the art will appreciate that, in general, the same may be said of “sender” and/or other entity-oriented terms as such terms are used herein.
Following are a series of flowcharts depicting implementations. For ease of understanding, the flowcharts are organized such that the initial flowcharts present implementations via an example implementation and thereafter the following flowcharts present alternate implementations and/or expansions of the initial flowchart(s) as either sub-component operations or additional component operations building on one or more earlier-presented flowcharts. Those having skill in the art will appreciate that the style of presentation utilized herein (e.g., beginning with a presentation of a flowchart(s) presenting an example implementation and thereafter providing additions to and/or further details in subsequent flowcharts) generally allows for a rapid and easy understanding of the various process implementations. In addition, those skilled in the art will further appreciate that the style of presentation used herein also lends itself well to modular and/or object-oriented program design paradigms.
Those skilled in the art will appreciate that the foregoing specific exemplary processes and/or devices and/or technologies are representative of more general processes and/or devices and/or technologies taught elsewhere herein, such as in the claims filed herewith and/or elsewhere in the present application.
Those having skill in the art will recognize that the state of the art has progressed to the point where there is little distinction left between hardware, software, and/or firmware implementations of aspects of systems; the use of hardware, software, and/or firmware is generally (but not always, in that in certain contexts the choice between hardware and software can become significant) a design choice representing cost vs. efficiency tradeoffs. Those having skill in the art will appreciate that there are various vehicles by which processes and/or systems and/or other technologies described herein can be effected (e.g., hardware, software, and/or firmware), and that the preferred vehicle will vary with the context in which the processes and/or systems and/or other technologies are deployed. For example, if an implementer determines that speed and accuracy are paramount, the implementer may opt for a mainly hardware and/or firmware vehicle; alternatively, if flexibility is paramount, the implementer may opt for a mainly software implementation; or, yet again alternatively, the implementer may opt for some combination of hardware, software, and/or firmware. Hence, there are several possible vehicles by which the processes and/or devices and/or other technologies described herein may be effected, none of which is inherently superior to the other in that any vehicle to be utilized is a choice dependent upon the context in which the vehicle will be deployed and the specific concerns (e.g., speed, flexibility, or predictability) of the implementer, any of which may vary. Those skilled in the art will recognize that optical aspects of implementations will typically employ optically-oriented hardware, software, and or firmware.
In some implementations described herein, logic and similar implementations may include software or other control structures suitable to operation. Electronic circuitry, for example, may manifest one or more paths of electrical current constructed and arranged to implement various logic functions as described herein. In some implementations, one or more media are configured to bear a device-detectable implementation if such media hold or transmit a special-purpose device instruction set operable to perform as described herein. In some variants, for example, this may manifest as an update or other modification of existing software or firmware, or of gate arrays or other programmable hardware, such as by performing a reception of or a transmission of one or more instructions in relation to one or more operations described herein. Alternatively or additionally, in some variants, an implementation may include special-purpose hardware, software, firmware components, and/or general-purpose components executing or otherwise invoking special-purpose components. Specifications or other implementations may be transmitted by one or more instances of tangible transmission media as described herein, optionally by packet transmission or otherwise by passing through distributed media at various times.
Alternatively or additionally, implementations may include executing a special-purpose instruction sequence or otherwise invoking circuitry for enabling, triggering, coordinating, requesting, or otherwise causing one or more occurrences of any functional operations described above. In some variants, operational or other logical descriptions herein may be expressed directly as source code and compiled or otherwise invoked as an executable instruction sequence. In some contexts, for example, C++ or other code sequences can be compiled directly or otherwise implemented in high-level descriptor languages (e.g., a logic-synthesizable language, a hardware description language, a hardware design simulation, and/or other such similar mode(s) of expression). Alternatively or additionally, some or all of the logical expression may be manifested as a Verilog-type hardware description or other circuitry model before physical implementation in hardware, especially for basic operations or timing-critical applications. Those skilled in the art will recognize how to obtain, configure, and optimize suitable transmission or computational elements, material supplies, actuators, or other common structures in light of these teachings.
The foregoing detailed description has set forth various embodiments of the devices and/or processes via the use of block diagrams, flowcharts, and/or examples. Insofar as such block diagrams, flowcharts, and/or examples contain one or more functions and/or operations, it will be understood by those within the art that each function and/or operation within such block diagrams, flowcharts, or examples can be implemented, individually and/or collectively, by a wide range of hardware, software, firmware, or virtually any combination thereof. In one embodiment, several portions of the subject matter described herein may be implemented via Application Specific Integrated Circuits (ASICs), Field Programmable Gate Arrays (FPGAs), digital signal processors (DSPs), or other integrated formats. However, those skilled in the art will recognize that some aspects of the embodiments disclosed herein, in whole or in part, can be equivalently implemented in integrated circuits, as one or more computer programs running on one or more computers (e.g., as one or more programs running on one or more computer systems), as one or more programs running on one or more processors (e.g., as one or more programs running on one or more microprocessors), as firmware, or as virtually any combination thereof, and that designing the circuitry and/or writing the code for the software and or firmware would be well within the skill of one of skill in the art in light of this disclosure. In addition, those skilled in the art will appreciate that the mechanisms of the subject matter described herein are capable of being distributed as a program product in a variety of forms, and that an illustrative embodiment of the subject matter described herein applies regardless of the particular type of signal bearing medium used to actually carry out the distribution. Examples of a signal bearing medium include, but are not limited to, the following: a recordable type medium such as a floppy disk, a hard disk drive, a Compact Disc (CD), a Digital Video Disk (DVD), a digital tape, a computer memory, etc.; and a transmission type medium such as a digital and/or an analog communication medium (e.g., a fiber optic cable, a waveguide, a wired communications link, a wireless communication link (e.g., transmitter, receiver, transmission logic, reception logic, etc.), etc.).
In a general sense, those skilled in the art will recognize that the various embodiments described herein can be implemented, individually and/or collectively, by various types of electro-mechanical systems having a wide range of electrical components such as hardware, software, firmware, and/or virtually any combination thereof; and a wide range of components that may impart mechanical force or motion such as rigid bodies, spring or torsional bodies, hydraulics, electro-magnetically actuated devices, and/or virtually any combination thereof. Consequently, as used herein “electro-mechanical system” includes, but is not limited to, electrical circuitry operably coupled with a transducer (e.g., an actuator, a motor, a piezoelectric crystal, a Micro Electro Mechanical System (MEMS), etc.), electrical circuitry having at least one discrete electrical circuit, electrical circuitry having at least one integrated circuit, electrical circuitry having at least one application specific integrated circuit, electrical circuitry forming a general purpose computing device configured by a computer program (e.g., a general purpose computer configured by a computer program which at least partially carries out processes and/or devices described herein, or a microprocessor configured by a computer program which at least partially carries out processes and/or devices described herein), electrical circuitry forming a memory device (e.g., forms of memory (e.g., random access, flash, read only, etc.)), electrical circuitry forming a communications device (e.g., a modem, communications switch, optical-electrical equipment, etc.), and/or any non-electrical analog thereto, such as optical or other analogs. Those skilled in the art will also appreciate that examples of electro-mechanical systems include but are not limited to a variety of consumer electronics systems, medical devices, as well as other systems such as motorized transport systems, factory automation systems, security systems, and/or communication/computing systems. Those skilled in the art wilt recognize that electro-mechanical as used herein is not necessarily limited to a system that has both electrical and mechanical actuation except as context may dictate otherwise.
In a general sense, those skilled in the art will recognize that the various aspects described herein which can be implemented, individually and/or collectively, by a wide range of hardware, software, firmware, and/or any combination thereof can be viewed as being composed of various types of “electrical circuitry.” Consequently, as used herein “electrical circuitry” includes, but is not limited to, electrical circuitry having at least one discrete electrical circuit, electrical circuitry having at least one integrated circuit, electrical circuitry having at least one application specific integrated circuit, electrical circuitry forming a general purpose computing device configured by a computer program (e.g., a general purpose computer configured by a computer program which at least partially carries out processes and/or devices described herein, or a microprocessor configured by a computer program which at least partially carries out processes and/or devices described herein), electrical circuitry forming a memory device (e.g., forms of memory (e.g., random access, flash, read only, etc.)), and/or electrical circuitry forming a communications device (e.g., a modem, communications switch, optical-electrical equipment, etc.). Those having skill in the art will recognize that the subject matter described herein may be implemented in an analog or digital fashion or some combination thereof.
Those skilled in the art will recognize that at least a portion of the devices and/or processes described herein can be integrated into a data processing system. Those having skill in the art will recognize that a data processing system generally includes one or more of a system unit housing, a video display device, memory such as volatile or non-volatile memory, processors such as microprocessors or digital signal processors, computational entities such as operating systems, drivers, graphical user interfaces, and applications programs, one or more interaction devices (e.g., a touch pad, a touch screen, an antenna, etc.), and/or control systems including feedback loops and control motors (e.g., feedback for sensing position and/or velocity; control motors for moving and/or adjusting components and/or quantities). A data processing system may be implemented utilizing suitable commercially available components, such as those typically found in data computing/communication and/or network computing/communication systems.
Those skilled in the art will recognize that it is common within the art to implement devices and/or processes and/or systems, and thereafter use engineering and/or other practices to integrate such implemented devices and/or processes and/or systems into more comprehensive devices and/or processes and/or systems. That is, at least a portion of the devices and/or processes and/or systems described herein can be integrated into other devices and/or processes and/or systems via a reasonable amount of experimentation. Those having skill in the art will recognize that examples of such other devices and/or processes and/or systems might include—as appropriate to context and application—all or part of devices and/or processes and/or systems of (a) an air conveyance (e.g., an airplane, rocket, helicopter, etc.), (b) a ground conveyance (e.g., a car, truck, locomotive, tank, armored personnel carrier, etc.), (c) a building (e.g., a home, warehouse, office, etc.), (d) an appliance (e.g., a refrigerator, a washing machine, a dryer, etc.), (e) a communications system (e.g., a networked system, a telephone system, a Voice over IP system, etc.), (f) a business entity (e.g., an Internet Service Provider (ISP) entity such as Comcast Cable, Qwest, Southwestern Bell, etc.), or (g) a wired/wireless services entity (e.g., Sprint, Cingular, Nextel, etc.), etc.
In certain cases, use of a system or method may occur in a territory even if components are located outside the territory. For example, in a distributed computing context, use of a distributed computing system may occur in a territory even though parts of the system may be located outside of the territory (e.g., relay, server, processor, signal-bearing medium, transmitting computer, receiving computer, etc. located outside the territory).
A sale of a system or method may likewise occur in a territory even if components of the system or method are located and/or used outside the territory.
Further, implementation of at least part of a system for performing a method in one territory does not preclude use of the system in another territory.
All of the above U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in any Application Data Sheet, are incorporated herein by reference, to the extent not inconsistent herewith.
One skilled in the art will recognize that the herein described components (e.g., operations), devices, objects, and the discussion accompanying them are used as examples for the sake of conceptual clarity and that various configuration modifications are contemplated. Consequently, as used herein, the specific exemplars set forth and the accompanying discussion are intended to be representative of their more general classes. In general, use of any specific exemplar is intended to be representative of its class, and the non-inclusion of specific components (e.g., operations), devices, and objects should not be taken limiting.
Although user 118 is shown/described herein as a single illustrated figure, those skilled in the art will appreciate that user 118 may be representative of a human user, a robotic user (e.g., computational entity), and/or substantially any combination thereof (e.g., a user may be assisted by one or more robotic agents) unless context dictates otherwise. Those skilled in the art will appreciate that, in general, the same may be said of “sender” and/or other entity-oriented terms as such terms are used herein unless context dictates otherwise.
With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations are not expressly set forth herein for sake of clarity.
The herein described subject matter sometimes illustrates different components contained within, or connected with, different other components. It is to be understood that such depicted architectures are merely exemplary, and that in fact many other architectures may be implemented which achieve the same functionality. In a conceptual sense, any arrangement of components to achieve the same functionality is effectively “associated” such that the desired functionality is achieved. Hence, any two components herein combined to achieve a particular functionality can be seen as “associated with” each other such that the desired functionality is achieved, irrespective of architectures or intermedial components. Likewise, any two components so associated can also be viewed as being “operably connected”, or “operably coupled,” to each other to achieve the desired functionality, and any two components capable of being so associated can also be viewed as being “operably couplable,” to each other to achieve the desired functionality. Specific examples of operably couplable include but are not limited to physically mateable and/or physically interacting components, and/or wirelessly interactable, and/or wirelessly interacting components, and/or logically interacting, and/or logically interactable components.
In some instances, one or more components may be referred to herein as “configured to,” “configurable to,” “operable/operative to,” “adapted/adaptable,” “able to,” “conformable/conformed to,” etc. Those skilled in the art will recognize that “configured to” can generally encompass active-state components and/or inactive-state components and/or standby-state components, unless context requires otherwise.
White particular aspects of the present subject matter described herein have been shown and described, it will be apparent to those skilled in the art that, based upon the teachings herein, changes and modifications may be made without departing from the subject matter described herein and its broader aspects and, therefore, the appended claims are to encompass within their scope all such changes and modifications as are within the true spirit and scope of the subject matter described herein. It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to claims containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that typically a disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms unless context dictates otherwise. For example, the phrase “A or B” will be typically understood to include the possibilities of “A” or “B” or “A and B.”
With respect to the appended claims, those skilled in the art will appreciate that recited operations therein may generally be performed in any order. Also, although various operational flows are presented in a sequence(s), it should be understood that the various operations may be performed in other orders than those which are illustrated, or may be performed concurrently. Examples of such alternate orderings may include overlapping, interleaved, interrupted, reordered, incremental, preparatory, supplemental, simultaneous, reverse, or other variant orderings, unless context dictates otherwise. Furthermore, terms like “responsive to,” “related to,” or other past-tense adjectives are generally not intended to exclude such variants, unless context dictates otherwise.
While various aspects and embodiments have been disclosed herein, other aspects and embodiments will be apparent to those skilled in the art. The various aspects and embodiments disclosed herein are for purposes of illustration and are not intended to be limiting, with the true scope and spirit being indicated by the following claims.
The present application is related to and claims the benefit of the earliest available effective filing date(s) from the following listed application(s) (the “Related Applications”) (e.g., claims earliest available priority dates for other than provisional patent applications or claims benefits under 35 USC § 119(e) for provisional patent applications, for any and all parent, grandparent, great-grandparent, etc. applications of the Related Application(s)). Related Applications: For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION TREATMENT SELECTION METHODS AND SYSTEMS, naming Roderick A. Hyde; Muriel Y. Ishikawa; Eric C. Leuthardt; Royce A. Levien; Robert W. Lord; Mark A. Malamud; Elizabeth A. Sweeney; Lowell L. Wood, Jr.; and Victoria Y. H. Wood as inventors, filed Apr. 24, 2008, application Ser. No. 12/150,122, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION TREATMENT MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed May 13, 2008, application Ser. No. 12/152,266, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION TREATMENT ALTERATION METHODS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed May 21, 2008, application Ser. No. 12/154,275, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION THERAPEUTIC PRODUCTS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed May 30, 2008, application Ser. No. 12/156,440, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled SIDE EFFECT AMELIORATING COMBINATION THERAPEUTIC PRODUCTS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 5, 2008, application Ser. No. 12/156,949, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION TREATMENT MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 6, 2008, application Ser. No. 12/157,160, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION TREATMENT SELECTION METHODS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 13, 2008, application Ser. No. 12/157,922, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION TREATMENT MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 13, 2008, application Ser. No. 12/157,989, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled COMBINATION TREATMENT ALTERATION METHODS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 19, 2008, application Ser. No. 12/214,547, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled METHODS AND SYSTEMS FOR MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 3, 2008, application Ser. No. 12/217,509, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled METHODS AND SYSTEMS FOR MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 7, 2008, application Ser. No. 12/217,620, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled METHODS AND SYSTEMS FOR MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 15, 2008, application Ser. No. 12/218,503, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled METHODS AND SYSTEMS FOR MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 16, 2008, application Ser. No. 12/218,627, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date.For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States patent application entitled SYSTEMS AND APPARATUS FOR MEASURING A BIOACTIVE AGENT EFFECT, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 25, 2008, application Ser. No. 12/220,706, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date. For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation-in-part of United States Patent Application entitled METHODS AND SYSTEMS FOR MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Aug. 22, 2008, application Ser. No. 12/229,531, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date. For purposes of the USPTO extra-statutory requirements, the present application constitutes a continuation of United States Patent Application entitled METHODS AND SYSTEMS FOR MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Apr. 5, 2013, application Ser. No. 13/857,721, which is currently co-pending, or is an application of which a currently co-pending application is entitled to the benefit of the filing date. The United States Patent Office (USPTO) has published a notice to the effect that the USPTO's computer programs require that patent applicants reference both a serial number and indicate whether an application is a continuation or continuation-in-part. Stephen G. Kunin, Benefit of Prior-Filed Application, USPTO Official Gazette Mar. 18, 2003, available at http://www.uspto.gov/web/offices/com/sol/og/2003/week11/patbene.htm. The present Applicant Entity (hereinafter “Applicant”) has provided above a specific reference to the application(s) from which priority is being claimed as recited by statute. Applicant understands that the statute is unambiguous in its specific reference language and does not require either a serial number or any characterization, such as “continuation” or “continuation-in-part,” for claiming priority to U.S. patent applications. Notwithstanding the foregoing, Applicant understands that the USPTO's computer programs have certain data entry requirements, and hence Applicant is designating the present application as a continuation-in-part of its parent applications as set forth above, but expressly points out that such designations are not to be construed in any way as any type of commentary and/or admission as to whether or not the present application contains any new matter in addition to the matter of its parent application(s). All subject matter of the Related Applications and of any and all parent, grandparent, great-grandparent, etc. applications of the Related Applications is incorporated herein by reference to the extent such subject matter is not inconsistent herewith.
Number | Name | Date | Kind |
---|---|---|---|
3036568 | Stark | May 1962 | A |
4570640 | Barsa | Feb 1986 | A |
4734585 | Owers | Mar 1988 | A |
4755043 | Carter | Jul 1988 | A |
4962491 | Schaeffer | Oct 1990 | A |
4972841 | Iguchi | Nov 1990 | A |
4973149 | Hutchinson | Nov 1990 | A |
4974729 | Steinnagel | Dec 1990 | A |
5099463 | Lloyd et al. | Mar 1992 | A |
5135752 | Snipes | Aug 1992 | A |
5197941 | Whitaker | Mar 1993 | A |
5200891 | Kehr et al. | Apr 1993 | A |
5277188 | Selker | Jan 1994 | A |
5348268 | Klein | Sep 1994 | A |
5408443 | Weinberger | Apr 1995 | A |
5463564 | Agrafiotis et al. | Oct 1995 | A |
5508042 | Oshlack et al. | Apr 1996 | A |
5577981 | Jarvik | Nov 1996 | A |
5610674 | Martin | Mar 1997 | A |
5645072 | Thrall et al. | Jul 1997 | A |
5646629 | Loomis et al. | Jul 1997 | A |
5671752 | Sinderby et al. | Sep 1997 | A |
5678571 | Brown | Oct 1997 | A |
5722418 | Bro | Mar 1998 | A |
5722754 | Langner | Mar 1998 | A |
5724983 | Selker et al. | Mar 1998 | A |
5725472 | Weathers | Mar 1998 | A |
5822726 | Taylor et al. | Oct 1998 | A |
5845255 | Mayaud | Dec 1998 | A |
5846086 | Bizzi et al. | Dec 1998 | A |
5891049 | Cyrus et al. | Apr 1999 | A |
5913310 | Brown | Jun 1999 | A |
5919141 | Money et al. | Jul 1999 | A |
6012926 | Hodges et al. | Jan 2000 | A |
6014626 | Cohen | Jan 2000 | A |
6047203 | Sackner et al. | Apr 2000 | A |
6053866 | McLeod | Apr 2000 | A |
6067523 | Bair et al. | May 2000 | A |
6102846 | Patton et al. | Aug 2000 | A |
6149586 | Elkind | Nov 2000 | A |
6152563 | Hutchinson et al. | Nov 2000 | A |
6168562 | Miller et al. | Jan 2001 | B1 |
6186145 | Brown | Feb 2001 | B1 |
6198953 | Webster et al. | Mar 2001 | B1 |
6244987 | Ohsuga et al. | Jun 2001 | B1 |
6282458 | Murayama et al. | Aug 2001 | B1 |
6314384 | Goetz | Nov 2001 | B1 |
6315719 | Rode et al. | Nov 2001 | B1 |
6334778 | Brown | Jan 2002 | B1 |
6368111 | Legarda | Apr 2002 | B2 |
6383135 | Chikovani et al. | May 2002 | B1 |
6390453 | Frederickson et al. | May 2002 | B1 |
6397080 | Viktorsson et al. | May 2002 | B1 |
6421650 | Goetz et al. | Jul 2002 | B1 |
6425764 | Lamson | Jul 2002 | B1 |
6435878 | Reynolds et al. | Aug 2002 | B1 |
6436944 | Mayton | Aug 2002 | B1 |
6448030 | Rust et al. | Sep 2002 | B1 |
6487520 | Kurtzberg et al. | Nov 2002 | B1 |
6542858 | Grass et al. | Apr 2003 | B1 |
6561811 | Rapoza et al. | May 2003 | B2 |
6565359 | Calhoun et al. | May 2003 | B2 |
6579231 | Phipps | Jun 2003 | B1 |
6631291 | Vierto-Oja et al. | Oct 2003 | B2 |
6647358 | Grass et al. | Nov 2003 | B2 |
6702767 | Douglas et al. | Mar 2004 | B1 |
6723527 | Pettit et al. | Apr 2004 | B2 |
6807492 | Oren et al. | Oct 2004 | B2 |
6826498 | Birkner et al. | Nov 2004 | B2 |
6832178 | Fernandez et al. | Dec 2004 | B1 |
6852069 | Park | Feb 2005 | B2 |
6886653 | Bellehumeur | May 2005 | B1 |
6909359 | McGovern | Jun 2005 | B1 |
6947790 | Gevins et al. | Sep 2005 | B2 |
6952695 | Trinks et al. | Oct 2005 | B1 |
6968375 | Brown | Nov 2005 | B1 |
6997880 | Carlebach et al. | Feb 2006 | B2 |
7002476 | Rapchak | Feb 2006 | B2 |
7033025 | Winterbotham | Apr 2006 | B2 |
7039878 | Auer et al. | May 2006 | B2 |
7044911 | Drinan | May 2006 | B2 |
7049103 | Ishiguro et al. | May 2006 | B2 |
7076437 | Levy | Jul 2006 | B1 |
7084874 | Kurzweil | Aug 2006 | B2 |
7144680 | Park et al. | Dec 2006 | B2 |
7148208 | Barrkan et al. | Dec 2006 | B2 |
7161579 | Daniel | Jan 2007 | B2 |
7177675 | Suffin et al. | Mar 2007 | B2 |
7197492 | Sullivan | Mar 2007 | B2 |
7198044 | Trueba | Apr 2007 | B2 |
7198800 | Ko | Apr 2007 | B1 |
7226164 | Abourizk et al. | Jun 2007 | B2 |
7229288 | Stuart et al. | Jun 2007 | B2 |
7245956 | Matthews et al. | Jul 2007 | B2 |
7272431 | McGrath | Sep 2007 | B2 |
7294107 | Simon et al. | Nov 2007 | B2 |
7353065 | Morrell | Apr 2008 | B2 |
7461651 | Brown | Dec 2008 | B2 |
7513622 | Khaderi | Apr 2009 | B2 |
7575865 | Leamon et al. | Aug 2009 | B2 |
7623927 | Rezai | Nov 2009 | B2 |
7827044 | McCullough | Nov 2010 | B2 |
7890340 | Abraham-Fuchs et al. | Feb 2011 | B2 |
7942818 | Euliamo et al. | May 2011 | B2 |
8150509 | Kadhiresan et al. | Apr 2012 | B2 |
8150629 | Geerts et al. | Apr 2012 | B2 |
8160901 | Heywood et al. | Apr 2012 | B2 |
20010001144 | Kapp | May 2001 | A1 |
20010010541 | Fernandez et al. | Aug 2001 | A1 |
20020044152 | Abbott, III et al. | Apr 2002 | A1 |
20020091546 | Christakis et al. | Jul 2002 | A1 |
20020103428 | DeCharms | Aug 2002 | A1 |
20020103429 | DeCharms | Aug 2002 | A1 |
20020128061 | Blanco | Sep 2002 | A1 |
20020156453 | Pettis et al. | Oct 2002 | A1 |
20020165466 | Givens et al. | Nov 2002 | A1 |
20020198438 | Cromer et al. | Dec 2002 | A1 |
20030005924 | Rabinowitz et al. | Jan 2003 | A1 |
20030036683 | Kehr et al. | Feb 2003 | A1 |
20030036744 | Struys et al. | Feb 2003 | A1 |
20030065294 | Pickup et al. | Apr 2003 | A1 |
20030077300 | Wermeling | Apr 2003 | A1 |
20030139933 | Kimmel | Jul 2003 | A1 |
20030144884 | Mayaud | Jul 2003 | A1 |
20030214630 | Winterbotham | Nov 2003 | A1 |
20030225362 | Currie et al. | Dec 2003 | A1 |
20040010511 | Gogolak | Jan 2004 | A1 |
20040024287 | Patton et al. | Feb 2004 | A1 |
20040024616 | Spector et al. | Feb 2004 | A1 |
20040030581 | Leven | Feb 2004 | A1 |
20040078027 | Shachar | Apr 2004 | A1 |
20040078239 | Dacosta | Apr 2004 | A1 |
20040087576 | Haracz | May 2004 | A1 |
20040092809 | DeCharms | May 2004 | A1 |
20040093218 | Bezar | May 2004 | A1 |
20040123667 | McGrath | Jul 2004 | A1 |
20040127778 | Lambert et al. | Jul 2004 | A1 |
20040152622 | Keith et al. | Aug 2004 | A1 |
20040172285 | Gibson | Sep 2004 | A1 |
20040196184 | Hollander et al. | Oct 2004 | A1 |
20040208923 | David et al. | Oct 2004 | A1 |
20050007552 | Fergason et al. | Jan 2005 | A1 |
20050021372 | Mikkelsen et al. | Jan 2005 | A1 |
20050027284 | Lozano et al. | Feb 2005 | A1 |
20050054942 | Melker et al. | Mar 2005 | A1 |
20050054958 | Hoffmann | Mar 2005 | A1 |
20050065813 | Mishelevich | Mar 2005 | A1 |
20050075274 | Willmann et al. | Apr 2005 | A1 |
20050084523 | Shafer et al. | Apr 2005 | A1 |
20050086077 | Forman | Apr 2005 | A1 |
20050124851 | Patton et al. | Jun 2005 | A1 |
20050124866 | Elaz et al. | Jun 2005 | A1 |
20050124878 | Sharony | Jun 2005 | A1 |
20050148883 | Boesen | Jul 2005 | A1 |
20050165115 | Murphy et al. | Jul 2005 | A1 |
20050188853 | Scannell, Jr. | Sep 2005 | A1 |
20050197654 | Edman et al. | Sep 2005 | A1 |
20050234742 | Hodgdon | Oct 2005 | A1 |
20050240084 | Morice et al. | Oct 2005 | A1 |
20050277911 | Stewart et al. | Dec 2005 | A1 |
20060031099 | Vitello et al. | Feb 2006 | A1 |
20060058694 | Clark et al. | Mar 2006 | A1 |
20060059145 | Henschke et al. | Mar 2006 | A1 |
20060062852 | Holmes | Mar 2006 | A1 |
20060078604 | Kanios et al. | Apr 2006 | A1 |
20060084877 | Ujhazy et al. | Apr 2006 | A1 |
20060111644 | Guttag et al. | May 2006 | A1 |
20060161408 | Bachman et al. | Jul 2006 | A1 |
20060161456 | Barker et al. | Jul 2006 | A1 |
20060183980 | Yang | Aug 2006 | A1 |
20060235724 | Rosenthal | Oct 2006 | A1 |
20060241718 | Tyler et al. | Oct 2006 | A1 |
20060247489 | Carbis et al. | Nov 2006 | A1 |
20060252761 | David et al. | Nov 2006 | A1 |
20060265253 | Rao et al. | Nov 2006 | A1 |
20070016265 | Davoodi et al. | Jan 2007 | A1 |
20070060870 | Tolle et al. | Mar 2007 | A1 |
20070067186 | Brenner et al. | Mar 2007 | A1 |
20070072821 | Iakoubova et al. | Mar 2007 | A1 |
20070088404 | Wyler et al. | Apr 2007 | A1 |
20070098778 | Borsadia | May 2007 | A1 |
20070106179 | Bagha et al. | May 2007 | A1 |
20070112277 | Fischer et al. | May 2007 | A1 |
20070112624 | Jung et al. | May 2007 | A1 |
20070123783 | Chang | May 2007 | A1 |
20070136093 | Rankin et al. | Jun 2007 | A1 |
20070167853 | Melker et al. | Jul 2007 | A1 |
20070172814 | Li | Jul 2007 | A1 |
20070179534 | Firlik et al. | Aug 2007 | A1 |
20070191704 | DeCharms | Aug 2007 | A1 |
20070197882 | Smith et al. | Aug 2007 | A1 |
20070213981 | Meyerhoff et al. | Sep 2007 | A1 |
20070273504 | Tran | Nov 2007 | A1 |
20080045832 | McGrath | Feb 2008 | A1 |
20080046286 | Halsted | Feb 2008 | A1 |
20080076972 | Dorogusker et al. | Mar 2008 | A1 |
20080097167 | Yudkovitch et al. | Apr 2008 | A1 |
20080125978 | Robson et al. | May 2008 | A1 |
20080132383 | Einav et al. | Jun 2008 | A1 |
20080133265 | Silkaitis | Jun 2008 | A1 |
20080139870 | Gliner et al. | Jun 2008 | A1 |
20080139902 | Kotulla et al. | Jun 2008 | A1 |
20080146334 | Kil | Jun 2008 | A1 |
20080146888 | Azzaro et al. | Jun 2008 | A1 |
20080167571 | Gevins | Jul 2008 | A1 |
20080172044 | Shelton | Jul 2008 | A1 |
20080177197 | Lee et al. | Jul 2008 | A1 |
20080212847 | Davies et al. | Sep 2008 | A1 |
20080214902 | Lee et al. | Sep 2008 | A1 |
20080214903 | Orbach | Sep 2008 | A1 |
20080221847 | Fenetteau | Sep 2008 | A1 |
20080226730 | Schmitke et al. | Sep 2008 | A1 |
20080242947 | Jung et al. | Oct 2008 | A1 |
20080243544 | Cafer | Oct 2008 | A1 |
20080267447 | Kelusky et al. | Oct 2008 | A1 |
20080275731 | Rao et al. | Nov 2008 | A1 |
20080278682 | Huxlin et al. | Nov 2008 | A1 |
20080305518 | Klausen et al. | Dec 2008 | A1 |
20090009718 | Legatt | Jan 2009 | A1 |
20090036435 | Curry et al. | Feb 2009 | A1 |
20090048506 | Fong-Ichimura et al. | Feb 2009 | A1 |
20090093551 | Bhatia et al. | Apr 2009 | A1 |
20090149769 | Pettigrew | Jun 2009 | A1 |
20090171697 | Glauser et al. | Jul 2009 | A1 |
20090299763 | Sakurada | Dec 2009 | A1 |
20090306741 | Hogle et al. | Dec 2009 | A1 |
20090312817 | Hogle et al. | Dec 2009 | A1 |
20100015184 | Tuel | Jan 2010 | A1 |
20100094202 | Edginton et al. | Apr 2010 | A1 |
20100163027 | Hyde et al. | Jul 2010 | A1 |
20100168525 | Hyde et al. | Jul 2010 | A1 |
20100168602 | Hyde et al. | Jul 2010 | A1 |
20100324874 | Bangs et al. | Dec 2010 | A9 |
Number | Date | Country |
---|---|---|
2004-206578 | Jul 2004 | JP |
WO 9904043 | Jan 1999 | WO |
WO 2003048789 | Jun 2003 | WO |
WO 2006048417 | May 2006 | WO |
WO 2006090371 | Aug 2006 | WO |
WO 2007016241 | Feb 2007 | WO |
WO 2007068983 | Jun 2007 | WO |
WO 2007141373 | Dec 2007 | WO |
Entry |
---|
Gregg et al.; “Virtual reality in mental health”; Social Psychiatry and Psychiatric Epidemiology; Mar. 12, 2007; pp. 343-354; vol. 42. |
Greenblatt at al.; “Benzodiazepines: A Summary of Pharmacokinetic Properties; British Journal of Gamma Pharmacology”; 1981; pp. 11S-16S; vol. 11; MacMillan Ltd. Publisher. |
Otto et al.; “Benzodiazepine Use, Cognitive Impairment, and Cognitive-Behavioral Therapy for Anxiety Disorders: Issues in the Treatment of a Patient in Need”; Journal of Clinical Psychiatry; 2005; pp. 34-38; vol. 66 (Suppl. 2); Physicians Postgraduate Press Inc. |
Spiegel et al.; “Does Cognitive Behavior Therapy Assist Slow-Taper Alprazolam Discontinuation in Panic Disorder?”; American Journal of Psychiatry; Jun. 1994; pp. 876-881; vol. 151, No. 6; American Journal of Psychiatry. |
U.S. Appl. No. 12/315,366, Hyde et al. |
U.S. Appl. No. 12/315,072, Hyde et al. |
U.S. Appl. No. 12/290,456, Hyde et al. |
U.S. Appl. No. 12/290,227, Hyde et al. |
U.S. Appl. No. 12/287,886, Hyde et al. |
U.S. Appl. No. 12/287,686, Hyde et al. |
U.S. Appl. No. 12/286,751, Hyde et al. |
U.S. Appl. No. 12/286,730, Hyde et al. |
U.S. Appl. No. 12/283,742, Hyde et al. |
U.S. Appl. No. 12/283,619, Hyde et al. |
U.S. Appl. No. 12/229,612, Hyde et al. |
U.S. Appl. No. 12/584,200, Leuthardt et al. |
U.S. Appl. No. 12/584,129, Leuthardt et al. |
U.S. Appl. No. 12/462,404, Leuthardt et al. |
U.S. Appl. No. 12/462,344, Leuthardt et al. |
U.S. Appl. No. 12/462,197, Leuthardt et al. |
U.S. Appl. No. 12/462,129, Leuthardt et al. |
U.S. Appl. No. 12/460,327, Leuthardt et al. |
U.S. Appl. No. 12/460,252, Leuthardt et al. |
U.S. Appl. No. 12/459,623, Leuthardt et al. |
U.S. Appl. No. 12/459,493, Leuthardt et al. |
U.S. Appl. No. 12/459,386, Leuthardt et al. |
U.S. Appl. No. 12/459,287, Leuthardt et al. |
U.S. Appl. No. 12/459,195, Leuthardt et al. |
U.S. Appl. No. 12/459,029, Leuthardt et al. |
U.S. Appl. No. 12/455,308, Leuthardt et al. |
U.S. Appl. No. 12/455,148, Leuthardt et al. |
U.S. Appl. No. 12/387,961, Leuthardt et al. |
“Alter” Excerpt from the Merriam-Webster English Dictionary; Printed on Jul. 8, 2013; total of 4 pages; Merriam-Webster Incorporated. |
“Seromycin-cycloserine capsule”; Physician's Desk Reference Digital Drug Database; bearing a revision date of Jun. 2007; pp. 1-5; PDR Network, LLC. |
“Virtual-Reality Video Game Helps Link Depression to Specific Brain Area”; ScienceDaily; bearing a date of Mar. 2, 2007; p. 1; located at httg://v.rww.sciencedailv.corn/releases/2007/03/07030_1100807.btm; NIH (National Institute of Mental Health). |
Alan G. Sanfey, Social Decision-Making: Insights from Game Theory and Neuroscience, Science Magazine, Oct. 26, 2007, pp. 598-602, vol. 318, No. 5850. |
Albert Rizzo, et al., Virtual Therapeutic Environments with Haptics: An Interdisciplinary Approach for Developing Post-Stroke Rehabilitation S, CPSN 2005, Jun. 20-23, 2005, pp. 7076, Publisher: Proceedings of the 2005 International Conference on Computers for People with Special needs. |
Alessandra Gorin!, et al., Virtual Worlds, Real Healing, Science, Dec. 7, 2007, p. 1549, vol. 318 No. 5856, Publisher: AAAS. |
Axelrod, et al., Smoke and Mirrors: Gathering User Requirements for Emerging Affective Systems, Jun. 10, 2004, pp. 323-328, vol. 1, Publisher: 26th International Conference on Information Technology Interfaces, 2004. |
Banos et al.; “Virtual Reality Treatment of Flying Phobia”; IEEE Transactions on Information Technology in Biomedicine; Sep. 2002; pp. 206-212; vol. 6, No. 3; IEEE. |
Barbara Ortutay, Brain-Reading Headset to Sell for $299, Feb. 20, 2008, Publisher: Associated Press, Published in: US. |
Barrientos, Ruth M. et al.; “Memory for context is impaired by injecting anisomycin into dorsal hippocampus following context exploration”; Behavioural Brain Research; bearing a date of Aug. 21, 2002; pp. 299-306; vol. 134, Issues 1-2; Elsevier Science B.V. (abstract only). |
Beck et al.; “Virtual Reality Exposure Therapy for PTSD Symptoms After a Road Accident: An Uncontrolled Case Series”; Behavior Therapy; bearing a date of Sep. 22, 2006; pp. 39-48; vol. 38; Elsevier Ltd. |
Bonson, Katherine R.; “Hallucinogenic Drugs”; Encyclopedia of Life Sciences; bearing a date of 2001; DD. 1-7; Nature Publishing Group. |
Chen, Yang; “Olfactory display: development and application in virtual reality therapy”; Proceedings of the 16th International Conference on Artificial Reality and Telexistence—Workshops (ICAT 2006); Nov. 29,-Dec. 2, 2006; pp. 1-5; IEEE Computer Society; IEEE Computer Society Press, Los Alamitos, CA. |
Chu et al.; “Proust nose best: Odors are better cues of autobiographical memory”; Memory & Cognition; bearing a date of Jan. 23, 2002; pp. 511-518; vol. 30, No. 4; Psychonomic Society, Inc. |
Coelho et al.; “Research Article Deconstructing Acrophobia: Physiological and Psychological Precursors to Developing a Fear of Heights”; Depression and Anxiety; bearing a date of Apr. 8, 2010; nn. 864-870; vol. 27; Wiley-Liss, Inc. |
Cui et al.; “Nanowire Nanosensors for Highly Sensitive and Selective Detection of Biological and Chemical Species”; Science; Aug. 17, 2001; pp. 1289-1292; vol. 293; located at: vi'Ww.sciencemag_.orn. |
D. Shaw, et al., Anxiolytic Effects of Lavender Oil Inhalation on Open-Field Behaviour in Rats, Phytomedicine, Mar. 19, 2007, pp. 613-620, vol. 14. |
Dale A. Lawrence, et al., Human Perception of Friction in Haptic Interfaces, Proc. ASME Dynamic Systems and Control Division, Nov. 1998, pp. 287-294, vol. 64. |
Davis, Michael et al.; “Combining Pharmacotherapy With Cognitive Behavioral Therapy: Traditional and New Approaches”; Journal of Traumatic Stress; bearing a date of Oct. 2006; nn. 571-581; vol. 19, No. 5; InterScience. |
De Matthews, et al., Using and Understanding Medical Statistics, S. Karger Basel AG, 2007, pp. 111-127. |
Difede, Joann, Ph.D. et al.; “Virtual Reality Exposure Therapy for World Trade Center Post-traumatic Stress Disorder: A Case Report”; CyberPsychology & Behavior; 2002; DD. 529-535; vol. 5, No. 6; CyberPsychology & Behavior. |
E. Glenn Schellenberg, et al., Exposure to Music and Cognitive Performance: Tests of Children and Adults, Psychology of Music, 2007, pp. 5-19, vol. 35. |
E. Grossman, et al., Breathing-Control lowers Blood Pressure, Journal of Human Hypertension, Apr. 2001, pp. 263-269, vol. 15, No. 4, Publisher: Nature Publishing Group. |
Ekman et al.; “What the Face Reveals: Basic and Applied Studies of Spontaneous Expression Using the Facial Action Coding System (FACS)”; 1997; pp. 1-7; Oxford University Press, Inc. |
Elizabeth Von Muggenthaler, The Felid Purr: A Bio-Mechanical Healing Mechanism, Sep. 18, 2006, Publisher: 12th International Conference on Low Frequency Noise and Vibration and its Control. |
F. Joseph McClernon, et al, The Effects of Controlled Deep Breathing on Smoking Withdrawal Symptoms n Dependent Smokers, ScienceDirect, Jun. 2004, pp. 765-772, vol. 29, No. 4, Publisher: Elsevier Ltd. |
F.J. Canadas-Quesada, et al., Improvement of Perceived Stiffness Using Auditory Stimuli in Haptic Virtual Reality, IEEE Melecon, May 16-19, 2006. |
Fernando Patolsky, et al., Nanowire Sensors for Medicine and the Life Sciences, Future Medicine, Jun. 2006, pp. 51-65, vol. 1, No. 1. |
Foa et al.; “Guidelines for Treatment of PTSD”; Journal of Traumatic Stress; 2000; pp. 539-588; vol. 13, No. 4; Reprinted with permission from “Effective Treatments for PTSD”; F oa et al.; Guilford Press. |
G. Parker, et al., Prediction of Response to Antidepressant Medication by a Sign-Based Index of Melancholia, Australian and New Zealand Journal of Psychiatry, 1993, pp. 56-61, vol. 27, No. 1. |
Garcia-Palacios et al.; “Virtual reality in the treatment of spider phobia: A controlled study”; Behaviour Research and Therapy; bearing a date of Jul. 1, 2001; pp. 983-993; vol. 40; Elsevier Science Ltd. |
Gerardi et al.; “Virtual Reality Exposure Therapy Using a Virtual Iraq: Case Report”; Journal of Traumatic Stress; Apr. 2008; pp. 209-213; vol. 21, No. 2; 2008 International Society for Traumatic Stress Studies. |
Grollman, Arthur P.; “Inhibitors of Protein Biosynthesis”; The Journal of Biological Chemistry; bearing a date of Jul. 10, 1967; pp. 3266-3233; vol. 242, No. 13. |
Harland, C.J. et al.; “Electric potential probes—new directions in the remote sensing of the human body”; Measurement Science and Technology; bearing a date of 2002; pp. 163-169; vol. 13; Institute of Physics Publishing. |
Harland, CJ. et al.; “High Resolution Ambulatory Electrocardiographic Monitoring Using Wrist-Mounted Electric Potential Sensors”; Measuring Science and Technology; bearing a date of May 23, 2003; nn. 923-928; vol. 14; IOP Publishing Ltd. |
Harland, C.J. et al.; “Remote Detection of Human Electroencephalograms Using Ultrahigh Input Impedance Electric Potential Sensors”; Applied Physics Letters; bearing a date of Oct. 21, 2002; pp. 3284-3286; vol. 81, No. 17; American Institute of Physics. |
Hollifield, Michael, MD et al.; “Integrating Therapies for Anxiety Disorders”; Psychiatric Annals; May 2006; pp. 329-338; vol. 36, No. 5. |
Hunter G. Hoffman, et al., Analgesic Effects ofOpioids and Immersive Virtual Reality Distraction: Evidence from Subjective and Functional Brain Image Assessments, Anesthesia & Analgesia, 2007, pp. 1776-1783, vol. 105. |
Hunter G. Hoffman, Virtual-Reality Therapy, Scientific American, Jul. 26, 2004, pp. 60-65. |
IEEE 100: The Authoritative Dictionary of IEEE Standards Terms, Seventh Edition; The Institute of Electrical and Electronics Engineering Press. |
Igor Knez, Effects of Colour of Light on Nonvisual Psychological Processes, Jun. 2001, pp. 201-208, vol. 21, No. 2, Publisher: Journal of Environmental Psychology. |
J.A. Spencer, et al, White Noise and Sleep Induction, Archives of Disease in Childhood, 1990, pp. 135-137, vol. 65, Publisher: BMJ Publishing Group. |
J.N. Cohn, Introduction to Surrogate Markers, Circulation, 2004, pp. IV20-21, vol. 109, Publisher: American Heart Association. |
Jan A. Staessen, et al., Randomised Double-Blind Comparison of Placebo and Active Treatment for Older Patients With Isolated Systolic Hypertension, The Lancet, Sep. 13, 1997, pp. 757-764, vol. 350, No. 9080. |
Jennifer Vasterling, et al., Cognitive Distraction and Relaxation Training for the Control of Side Effects Due to Cancer Chemotherapy, Journal of Behavioral Medicine, Feb. 1993, pp. 65-80, vol. 16, No. 1, Publisher: Springer Netherlands. |
Jin-Lain Ming, et al., The Efficacy of Acupressure to Prevent Nausea and Vomiting in Post-Operative Patients, Journal of Advanced Nursing, Aug. 2002, pp. 343-351, vol. 39, No. 4. |
JM Jokiniitty, et al., Prediction of Blood Pressure Level and Need for Antihypertensive Medication: 10 Years of Follow-up, J. Hypertension, Jul. 2001, pp. 1193-1201, vol. 19, No. 7. |
K. Yamada, et al., Prediction of Medication Noncompliance in Outpatients with Schizophrenia: 2-year follow-up study, Psychiatry Research, 2004, pp. 61-69, vol. 141, No. 1. |
Kozarek, et al., Prospective Trial using Virtual Vision as Distraction Technique in Patients Undergoing Gastric Laboratory Procedures, Gastroenterology Nursing, Jan. 1997, pp. 12-14, vol. 20, No. 1. |
Kris Bosworth, et al., A computer-Based Violence Prevention Intervention for Young Adolescents: A Pilot Study, Adolescence, Winter 1998, pp. 785-796, vol. 33, No. 132, Publisher: Libra Publishers, Inc. |
Kuan Zhang, et al., Measurement of Human Daily Physical Activity, Obesity Research, Jan. 1, 2003, pp. 33-40, vol. 11, No. 1. |
Kuzma, John M., MD et al.: “Integrating Pharmacotherapy and Psychotherapy in the Management of Anxiety Disorders”; Current Psychiatry Reports; 2004; pp. 268-273; vol. 6; Current Science Inc. |
Laurent Jeanpierre, et al., Automated Medical Diagnosis with Fuzzy Stochastic Models: Monitoring Chronic Diseases, Acta Biotheoretica, 2004, pp. 291-311, vol. 52, No. 4, Publisher: Springer. |
Lee, Inn-Sook et al.; “Effects of Lavender Aromatherapy on Insomnia and Depression in Women College Students”; Journal of Korean Academy ofNursing; Feb. 2006; nn. 136-143; vol. 36, No. 1; Taehan Kanho Hakoe chi 36. |
Lee et al.; “Reconsolidation and Extinction of Conditioned Fear: Inhibition and Potentiation”; The Journal ofNeuroscience; Sep. 27, 2006; pp. 10051-10056; vol. 26, No. 39; Society for Neuroscience. |
Lehrner et al.; “Ambient odors of orange and lavender reduce anxiety and improve mood in a dental office”; Physiology & Behavior; Apr. 27, 2005; pp. 92-95; vol. 86; Elsevier Inc. |
Leonid Skorin, Jr., How to Diagnose and Manage Headaches, Review of Optometry Nov. 1999 pp. 73-76, vol. 136. |
Luc Marlier, et al., Olfactory Stimulation Prevents Apnea in Premature Newborns, Pediatrics, Jan. 3, 2005, pp. 83-88, vol. 115, No. 1. |
M.R. Basso, Jr., Neurobiological Relationships Between Ambient Lighting and the Startle Response to Acoustic Stress in Humans, Sep. 2001, pp. 147-157, vol. 110, No. 3-4, Publisher: International Journal of Neuroscience. |
M.R. Smith, et al., A Data Extrapolation Algorithm Using a Complex Domain Neuralnetwork, Circuits and Systems II: Analog and Digital Signal Processing, IEEE Transactions on, Feb. 1997, pp. 143-147, vol. 44, No. 2. |
Matthew M. Kurtz, et al., A Virtual Reality Apartment as a Measure of Medication Management Skills in Patients with Schizophrenia: A Pilot Study, Schizophrenia Bulletin, 2007, pp. 1162-1170, vol. 33, No. 5, Publisher: Oxford University Press. |
Maura Paul-Labrador, et al., Effects of a Randomized Controlled Trail of Transcendental Meditation on Components of the Metabolic Syndrome in Subjects With Coronary Artery Disease, Arch Intern Med, Jun. 12, 2006, pp. 1218-1224, vol. 166, Publisher: American Medical Society. |
Max Bayard, et al., Alcohol Withdrawal Syndrome, American Family Physician, Mar. 15, 2004, pp. 1443-1450, vol. 69, Published in: US. |
McKendree-Smith et al.; “Self-Administered Treatments for Depression: A Review”; Journal of Clinical Psychology; bearing a date of Mar. 2003; pp. 275-288; vol. 59, No. 3; Wiley Periodicals, Inc. |
Morishita et al, Induction of Mania in Depression by Paroxetine, Human Psychopharmacol, Oct. 2003, pp. 565-568, vol. 18, No. 7. |
Moss et al.; “Aromas of Rosemary and Lavender Essential Oils Differentially Affect Cognition and Mood in Healthy Adults”; Intern. J. Neuroscience; bearing a date of Jul. 24, 2002; pp. 15-38; vol. 113; Taylor & Francis. |
Mueller et al.; “Noradrenergic modulation of extinction learning and exposure therapy”; Behavioural Brain Research; bearing a date of Dec. 1, 2009; pp. 1-11; vol. 208; Elsevier B.V. |
Munjack, Dennis J. et al.; “Alprazolam, Propranolol, and Placebo in the Treatment of Panic Disorder and Agoraphobia with Panic Attacks”; Journal of Clinical Psychopharmacology; bearing a date of 1989; pp. 22-27; vol. 9, No. 1; Williams and Wilkins Co. |
Myers et al.; “Mechanisms of fear extinction”; Molecular Psychiatry; Dec. 12, 2006; pp. 120-150; vol. 12; Nature Publishing Group. |
Neda Gould, et al., Performance on a Virtual Reality Spatial Memory Navigation Task in Depressed Patients, American Journal of Psychiatry, Mar. 10, 2007, pp. 516-519, vol. 165. |
New Horizons of Nerve Repair: Biomedical Engineer Trips Up Proteins in Nerve Regeneration System, Science Daily, Jul. 26, 2002, Publisher: htt11://wwvv.sciencedailv.com/releases/2002/07/020725082253.htrn. |
New Mini-Sensor May Have Biomedical and Security Applications, Physorg.com, Nov. 1, 2007, Publisher: bttu://www.ghysorn:.com/newsll31 51078.btml. |
Pampallona et al; “Combined Pharmacotherapy and Psychological Treatment for Depression: A Systematic Review”; Arch Gen Psychiatry; bearing a date of Jul. 2004; pp. 714-719; vol. 61; American Medical Association. |
Paccoud et al.; “Report on the Impact of a User-Centered Approach and Usability Studies for Designing Mobile and Context-Aware Cognitive Orthosis”; Pervasive Computing for Quality of Life Enhancement; bearing a date of 2007, created on Aug. 25, 2016; pp. 179-187; Springer-Verlag Berlin Heidelberg. |
Pentland, Alex (Sandy); “Healthwear: Medical Technology Becomes Wearable”; Computer; May 2004; pp. 42-49; IEEE. |
Peter Clarke, IBEC Has a Brain Wave: Feed EEG Emotion Back Into Games, EE Times online, Nov. 1, 2007, Publisher: httn://www.eetirnes.eu/desiim/202801063. |
Phosphodiesterase Isoenzymes as Pharmacological Targets in the Treatment of Male Erectile Dysfunction, World Journal of Urology, Feb. 2001, pp. 14-22, vol. 19, No. 1. |
Piquepaille, Roland; “Virtual Reality Helps Diagnose Heart Defects”; bearing a date of Dec. 28, 2005; 2008 CNET Networks, Inc. |
Prance, R.J. et al.; “Adaptive Electric Potential Sensors for Smart Signal Acquisition and Processing”; Journal of Physics: Conference Series 76; Sensors and their Applications XIV (Sensors07); bearing a date of2007; pp. 1-5; IOP Publishing Ltd. |
Raymond W. Lam, et al., The Can-SAD Study: A Randomized Controlled Trial of the Effectiveness of Light Therapy and Fluoxetine in Patients With Winter Season Affected Disorder, May 2006, pp. 805-812, vol. 163, Publisher: American Journal of Psychiatry. |
Ressler et al.; “Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic”; Nature Neuroscience; Sep. 2007; pp. 1116-1124; vol. 10, No. 9; Nature Publishing Group. |
Ressler, Kerry J. et al.; “Cognitive Enhancers as Adjuncts to Psychotherapy Use ofD-Cycloserine in Phobic Individuals to Facilitate Extinction of Fear”; bearing a date of Nov. 2004; pp. 1136-1144; vol. 61; Arch Gen Psychiatry. |
Robert E.L. Faris, Cultural Isolation and the Schizophrenic Personality, The American Journal of Sociology, Sep. 1934, pp. 155-164, vol. 40, No. 2, Publisher: University of Chicago Press. |
Rothbaum, Barbara 0. et al.; “Applying Learning Principles to the Treatment of Post-Trauma Reactions”; Annals New York Academy of Sciences; bearing a date of 2003; DD. 112-121; vol. 1008; New York Academy of Sciences. |
Rothbaum et al.; “A Controlled Study of Virtual Reality Exposure Therapy for the Fear of Flying”; Journal of Consulting and Clinical Psychology; bearing a date of May 4, 2000; DD. 1020-1026; vol. 68, No. 6; American Psychological Association, Inc. |
Russell N. Carney, et al, Mnemonic Instruction, With a Focus on Transfer, Dec. 2000, pp. 783-790, vol. 92, Publisher: Journal of Educational Psychology. |
Sander Greenland, et al., Methods for Trend Estimation from Summarized Dose-Response Data, with Applications to Meta-Analysis, American Journal of Epidemiology, 1992, pp. 1301-1309, vol. 135, No. 11. |
Sandra L. Siedliecki, et al, Efect of Music on Power, Pain, Depression, and Disability, Journal of Advanced Nursing, Jan. 13, 2006, pp. 553-562, vol. 54, Publisher: Blackwell Publishing. |
Schiller et al.; “Preventing the return of fear in humans using reconsolidation update mechanisms”; Nature; Jan. 7, 2010; pp. 49-54; vol. 463; Macmillan Publishers Limited. |
Shelley Wiechman Askay, Using Hypnosis for Spinal Cord Injury Pain Management, Sci Forum Report, Sep. 11, 2007, Publisher: htto://sci.washington.edu/info/forums/renorts/hvnnosisfor sci nain.aso. |
Silva, Alcino J. et al.; “CREB and Memory”; Annu. Rev. Neurosci.; 1998; pp. 127-137; vol. 21; Annual Reviews Inc. |
Something in the Way He Moves, The Economist, Sep. 27, 2007, Publisher: htto://v.rww.economist.com/sc:ience/PrinterFriendlv.cfm?storv'id=986 1 4 1 2. |
Sulaiman, S. et al.; “Human Motion Analysis Using Virtual, Reality”; Research and Development, 2007; SCOReD 2007; 5th Student Conference; bearing a date of Dec. 11-12, 2007; pp. 1-4; IEEE; published in Selangor, Malaysia [Abstract Only]. |
T. Green, et al, PC-Based Medical Data Acquisition and Analysis, 1995, p. 159 Publisher: 8th IEEE Symposium on Computer-Based Medical Systems (CBMS '95). |
Tronson et al.; “Molecular Mechanisms of Memory Reconsolidation”; Nature Reviews Neuroscience; Apr. 2007; pp. 262-275; vol. 8; Nature Publishing Group. |
Yaiva, Guillaume et al.; “Immediate Treatment with Propranolol Decreases Posttraumatic Stress Disorder Two Months after Trauma”; Biological Psychiatry; 2003; DD. 947-949; vol. 54; Society of Biological Psychiatry. |
Vaiva et al.; “Fright (Effroi) and Other Peritraumatic Responses After a Serious Motor Vehicle Accident: Prospective Influence on Acute PTSD Development”; The Canadian Journal of Psychiatry—Original Research; bearing a date of Jul. 2003; pp. 395-401; vol. 48, No. 6. |
Van Gerwen et al.; “People Who Seek Help for Fear of Flying: Typology of Flying Phobics”; Behavior Therapy; bearing a date of Mar. 11, 1997; pp. 237-251; vol. 28; Association for Advancement of Behavior Therapy. |
Video Game May Help Detect Depression, New Scientist, Mar. 10, 2007, p. 18, No. 2594. |
Virtual Reality Games Used to Distract Young Burn Victims From Pain and Anxiety, Medical News Today, Sep. 29, 2007, Publisher: h,112;!/w,.v,v.medicalnewstod0_y.corn/articles/84055,.12h12. |
Virtual Reality Medical Center, , Publisher: httD://vvww.vmhobia.c:om/. |
Virtual Reality Pain Reduction, Human Interface Technology Lab (HITL), Apr. 18, 2008, pp. 1-3, Publisher: h,112;//hit1.washi11._gton.eduJ12roiects/vrnain/. |
Walshe et al.; “Exploring the Use of Computer Games and Virtual Reality in Exposure Therapy for Fear of Driving Following a Motor Vehicle Accident”; CyberPsychology & Behavior; bearing a date of2003; pp. 329-334; vol. 6, No. 3; Mary Ann Liebert, Inc. |
Wiederhold, Brenda K.; “The Use of Virtual Reality Technology in the Treatment of Anxiety Disorders”; Information Technologies in Medicine; bearing a date of2001; pp. 19-37; vol. II; John Wiley & Sons, Inc. |
Wiederhold et al.; “Fear of Flying: A Case Report Using Virtual Reality Therapy with Physiological Monitoring,” CyberPsychology & Behavior. Jan. 1998.97-103. Published Online:Jan. 29, 2009 (https://doi.org/10.1089/cpb.1998.1.97). |
Wiederhold et al.; “Physiological Monitoring as an Objective Tool in Virtual Reality Therapy”; CyberPsychology & Behavior; bearing a date of2002; pp. 77-82; vol. 5, No. 1; Mary Ann Liebert, Inc. |
Xueliang Huo, et al., A Wireless Pharmaceutical Compliance Monitoring System Based on Magneto-Inductive Sensors, Sensors Journal, IEEE, Dec. 2007, pp. 1171-1719, vol. 7, No. 12, Published in: US. |
Yoshino, Kohzoh et al.; “An Algorithm for Detecting Startle State Based on Physiological Signals”; ScienceDirect; bearing a date of2006; pp. 1-3; located at http://,vv,w.sciencedirect.com/science?ob=ArticleJRL&_udi=B6V5S-4M3BCCB-_1_&_user=1_O&coverDate=03%,2F3_1%2F2007&_alid=918001_417&_rdoc=2&_fm1=hig.111&_ori_g=search&_cdi=5794&_sort=d&_docanchor=&view=c&ct=5&_acct=COOOO50221&_version=_1_&_ml_Version=O&userid=1O&md5=bc77_a78ef5a694a6ecf4dc397_676fl4f; Elsevier B.V. [Abstract Only]. |
Number | Date | Country | |
---|---|---|---|
20170100540 A1 | Apr 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13857721 | Apr 2013 | US |
Child | 15349974 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12229531 | Aug 2008 | US |
Child | 13857721 | US | |
Parent | 12220706 | Jul 2008 | US |
Child | 12229531 | US | |
Parent | 12218627 | Jul 2008 | US |
Child | 12220706 | US | |
Parent | 12218503 | Jul 2008 | US |
Child | 12218627 | US | |
Parent | 12217620 | Jul 2008 | US |
Child | 12218503 | US | |
Parent | 12217509 | Jul 2008 | US |
Child | 12217620 | US | |
Parent | 12156949 | Jun 2008 | US |
Child | 12217509 | US | |
Parent | 12156440 | May 2008 | US |
Child | 12156949 | US | |
Parent | 12214547 | Jun 2008 | US |
Child | 12156440 | US | |
Parent | 12154275 | May 2008 | US |
Child | 12214547 | US | |
Parent | 12157989 | Jun 2008 | US |
Child | 12154275 | US | |
Parent | 12157160 | Jun 2008 | US |
Child | 12157989 | US | |
Parent | 12152266 | May 2008 | US |
Child | 12157160 | US | |
Parent | 12157922 | Jun 2008 | US |
Child | 12152266 | US | |
Parent | 12150122 | Apr 2008 | US |
Child | 12157922 | US |